Dr. Roberts has authored over 130 peer-reviewed publications in leading medical and public health journals, as well as several book chapters and other contributions. He has also presented at numerous national and international conferences, including the Alzheimer’s Association International Conference, American Society of Human Genetics, and American Society for Bioethics and the Humanities. Below are selected examples of this work. For a full listing see Dr. Roberts’ CV below.
Roberts JS, Ferber R, Blacker D, Rumbaugh M, Grill J, for the Advisory Group on Risk Evidence Education for Dementia (AGREED) (2021). Disclosure of individual research results at federally funded Alzheimer’s Disease Research Centers. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 7:e12213.
Roberts JS, Patterson A, Uhlmann W (2020). Genetic testing for neurodegenerative diseases: Ethical and health communication challenges. Neurobiology of Disease, 141. [PMID 32302673]
Roberts JS. (2019). Assessing the psychological impact of genetic susceptibility testing. Hastings Center Report, 49, S38-S43.
Roberts JS, Gornick MR. (2019). Ethical, legal, and social implications of precision cancer medicine. In S Roychowdhury, E Van Allen (Eds.), Precision Cancer Medicine (pp. 129-43). Springer Publishing.
Roberts JS, Gornick M, Le LQ, Bartnik N, Zikmund-Fisher B, Chinnaiyan A. (2019). Next-generation sequencing in precision oncology: Patient understanding and expectations. Cancer Medicine, 8(1), 227-37.
Roberts JS, Robinson JO, Diamond PM, Bharadwaj A, Christensen KD, Lee KB, Green RC, McGuire AL. (2018). Patient understanding of, satisfaction with, and perceived utility of whole genome sequencing: Findings from the MedSeq Project. Genetics in Medicine, 20(9):1069-1076.
Roberts JS, Gornick MC, Carere DA, Uhlmann WR, Ruffin MT, Green RC (2017). Direct-to-consumer genetic testing: User motivations, decision making, and perceived utility of results. Public Health Genomics, 20:36-45.
Roberts JS, Dolinoy DC, Tarini BA (2014). Emerging issues in public health genomics. Annual Review of Genomics and Human Genetics, 15, 461-480.
Roberts JS, Connell CM, McLaughlin S (2014). Public knowledge and beliefs about risk and protective factors for Alzheimer’s disease: Findings from the Health and Retirement Study. Alzheimer’s and Dementia, 10(5) S381-S389.
Roberts JS, Dunn L, Rabinovici, G (2013). Amyloid imaging, risk disclosure, and Alzheimer’s disease: Ethical and practical issues. Neurodegenerative Disease Management, 3(3) 219-229.
Roberts JS, Chen C, Uhlmann WR, Green RC (2012). Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer’s disease: The REVEAL Study. Genetics In Medicine, 14, 742-748.
Roberts JS, Christensen KD, Green RC (2011). Using Alzheimer’s disease as a model for genetic risk disclosure: Implications for personal genomics. Clinical Genetics, 80, 407-414.
Roberts JS, Shalowitz DI, Christensen KD, Everett J, Kim S, Raskin L, Gruber SB (2010). Returning individual research results: Development of a cancer genetics education and risk communication protocol. Journal of Empirical Research on Human Research Ethics, 3, 17-30.
Roberts JS, Karlawish J, Uhlmann WR, Petersen R, Green RC (2010). Mild cognitive impairment in clinical care: A survey of neurologists’ attitudes and practices. Neurology, 75, 425-431.
Roberts JS. (2020, July). “Can Alzheimer’s Disease Be Prevented?” Talk given as part of Michigan Alzheimer’s Disease Center speaker series.
Roberts JS. (2020 July). “Practical & Ethical Issues in APOE Genotype Disclosure.” Talk given as part of the Alzheimer’s Association International Conference.
News Media & Blog Posts